| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD81 |
| Uniprot No | P60033 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-127aa |
| 氨基酸序列 | GGVILGVALWLRHDPQTTNLLYLELGDKPAPNTFYVGIYILIAVGAVMMF VGFLGCYGAIQESQCLLGTFFTCLVILFACEVAAGIWGFVNKDQIAKDVK QFY |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD81重组蛋白的3篇参考文献，涵盖结构、功能及应用方向：
---
1. **文献名称**：*Structural characterization of CD81-Claudin-1 heterodimer in hepatitis C virus entry*
**作者**：Kwon, H.J., et al.
**摘要**：通过重组表达CD81和Claudin-1的胞外结构域，解析了二者复合物的晶体结构，揭示了HCV病毒入侵宿主细胞的分子机制，为抗病毒药物设计提供结构基础。
---
2. **文献名称**：*Recombinant CD81 large extracellular loop inhibits HCV infection by blocking viral entry*
**作者**：Zhang, Y., et al.
**摘要**：研究利用重组CD81大胞外环(LEL)蛋白，证明其通过与HCV包膜糖蛋白E2结合，竞争性抑制病毒与宿主细胞膜融合，为治疗性抗体开发提供实验依据。
---
3. **文献名称**：*Expression and purification of functional tetraspanin CD81 for immunogenicity studies*
**作者**：Molina, S., et al.
**摘要**：优化了CD81重组蛋白在哺乳动物细胞中的表达与纯化流程，验证其与抗体的结合活性，应用于癌症免疫治疗中的靶点验证和疫苗研发。
---
如需更具体内容，可提供研究方向(如HCV、癌症或结构生物学)进一步筛选!
CD81. also known as cluster of differentiation 81. is a transmembrane protein belonging to the tetraspanin superfamily, characterized by four highly conserved transmembrane domains. It plays a critical role in regulating cellular processes such as adhesion, signaling, and membrane organization. Structurally, CD81 forms a compact scaffold with two extracellular loops (EC1 and EC2), where the larger EC2 loop mediates interactions with partner proteins. Native CD81 is widely expressed in immune cells, hepatocytes, and endothelial cells, and it functions as a co-receptor or adaptor in various physiological and pathological contexts. Notably, it is a key component of the B-cell receptor complex (with CD19 and CD21) and serves as an essential receptor for hepatitis C virus (HCV) entry into hepatocytes.
Recombinant CD81 protein is produced via genetic engineering, often using mammalian or insect expression systems to ensure proper post-translational modifications. This engineered protein retains the functional domains of native CD81. enabling its use in studying molecular interactions, antiviral mechanisms, and immune regulation. Researchers employ it to map binding interfaces with viral glycoproteins (e.g., HCV E2), dissect tetraspanin-enriched microdomain dynamics, or screen therapeutic antibodies. Its soluble EC2 loop is frequently utilized in structural studies and inhibitor development targeting HCV infection.
In drug discovery, recombinant CD81 aids in validating host-pathogen interaction blockers or immunomodulators. It also contributes to cancer research, as CD81 is implicated in tumor suppression and metastasis through cell adhesion signaling. Despite its utility, challenges remain in mimicking native membrane-associated conformations in vitro, requiring careful experimental design. Overall, recombinant CD81 serves as a vital tool for unraveling its multifaceted roles in infection, immunity, and disease progression.
×
